Sales data from Greece’s pharmaceutical market highlights the dominance of chronic conditions—especially diabetes, cardiovascular, thyroid, and neurological disorders—which account for about 55% of total drug spending. At the same time, rising demand for obesity treatments points to a growing cost burden.
In 2025, around 430 million medicine packs were sold across roughly 3,800 products, with just 50 prescription drugs making up a quarter of total sales. Together, the top ten best-sellers offer a clear snapshot of the country’s most common health issues.
The Top 10 Most Popular Prescription Drugs
Levothyroxine
With 10.2 million boxes sold, this thyroid hormone treatment leads the list, highlighting the widespread prevalence of thyroid disorders, especially among women.
Acetylsalicylic Acid
This aspirin-based antithrombotic recorded 9.8 million sales, reflecting ongoing cardiovascular risks, particularly stroke prevention needs.
Furosemide
A key diuretic for hypertension and fluid retention, furosemide reached 4.8 million units, underscoring the burden of heart-related conditions.
Metformin
Also at 4.8 million units, this cornerstone diabetes drug points to the high number of Greeks managing type 2 diabetes.
Alprazolam
With nearly 4 million sales, this anti-anxiety medication signals significant levels of stress and mental health challenges.
Atorvastatin
A leading cholesterol-lowering statin, with around 4 million units sold, reflecting widespread issues with high cholesterol.
Amoxicillin
This antibiotic saw 3.3 million sales, boosted by seasonal infections and increased demand during winter months.
Esomeprazole
Used for gastric protection, it reached 3 million units, indicating common digestive issues—though possibly overprescribed.
Bisoprolol
At 2.3 million packages, this beta-blocker further highlights the prevalence of cardiovascular disease.
Folic Acid
With 2.4 million units sold, this supplement plays a key role in preventing and treating anemia.
Beyond the top ten, obesity treatments are expanding rapidly. Tirzepatide jumped to 300,000 units in 2025—up from just a few thousand—generating around 100 million euros, with sales expected to double in 2026.
Semaglutide also surged, reaching 1.32 million units (+40%) and over 130 million euros in revenue, reflecting its growing role in both diabetes care and weight management.
At the same time, a strong flu season drove antiviral demand, with oseltamivir sales rising 75% to 477,000 units.
Overall, these trends highlight not just drug consumption, but the mounting pressure of chronic illness, obesity, and seasonal outbreaks on Greece’s healthcare landscape.
